Plaintiffs lawyers suing over the breast cancer drug Taxotere filed motions this week to ensure that the first bellwether trial against Sanofi-Aventis U.S. LLC is not about them.
“Plaintiff anticipates that Sanofi may attempt to alienate the jury by converting the trial into a referendum on lawful practices by plaintiff attorneys,” wrote lead trial counsel Darin Schanker, of Denver’s Bachus & Schanker, and Rand Nolen, of Fleming, Nolen & Jez in Houston, in a motion filed ahead of a trial scheduled for Sept. 16.
